Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: October 15, 2009
Last updated: January 28, 2015
Last verified: January 2015

This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Prediabetic State
Drug: ACZ885
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of participants with adverse events, serious adverse events and death [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
    Participants were monitored for adverse events, serious adverse events and death throughout the study.

  • Change from baseline in aortic distensibility [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Two axial, ECG-gated, steady state free precession (SSFP) 'cine' images were acquired during breath-hold to determine aortic distensibility. The first image was obtained at the level of the right pulmonary artery through the ascending and proximal descending aorta and the second through the distal aorta below the diaphragm. Imaging of the aorta also enabled evaluation of the plaque burden and additional vascular function measures including the arterial strain.

  • Change from baseline in plaque burden (aortic vessel wall area and carotid vessel wall area) [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    For assessment of atherosclerotic plaque burden of the aorta, vessel wall images of the aorta were acquired with an ECG gated double-inversion recovery (black blood) fast spin echo sequence applied breath-holding. Using an oblique sagittal image of the aorta as a pilot, serial axial images were acquired to cover a section of the descending thoracic aorta. The midpoint of the right pulmonary artery in cross section was used as the anatomical reference for the first slice in baseline and follow-up scans. For assessment of the atherosclerotic plaque burden in the carotids, vessel wall images were acquired with an axial ECG gated T2 weighted black blood sequence. The carotid bifurcation was used as the anatomical reference for all three imaging time points with axial slice planes acquired above and below the bifurcation region.

Secondary Outcome Measures:
  • Change from baseline in pulse wave velocity and puse wave velocity error [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.

  • Change from baseline in plaque composition [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    During the carotid MRI acquisition, in addition to the T2 weighted ECG gated double inversion fast spin echo sequences T1 and PD weighted sequences were acquired. In combination with the T2 weighted images, the multi-contrast images were analyzed to determine regions of interest with contrast patterns consistent with the presence of necrotic lipid core, calcification and fibrous tissue.

  • Change from baseline in aortic strain [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Arterial strain was computed directly from the cine SSFP images and the change in lumen diameters over the cardiac cycle. The value was independent of pulse pressure.

  • Change from baseline in high sensitivity C-reactive protein (hsCRP) [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Blood samples were collected to analyze hsCRP.

  • Pharmacokinetics of ACZ885: serum concentration [ Time Frame: day 1, pre-dose, 4 hours, day 7, day 14, day 30, day 60, day 90, day 120, day 150, day 180, day 210, day 240, day 270, day 300, day 330, day 360, day 390, day 420, day 450 ] [ Designated as safety issue: No ]
    Blood serum samples were collected to analyze ACZ885 concentrations.

  • Change from baseline in fasting plasma glucose [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Blood samples were collected to analyze fasting plasma glucose.

  • Change from baseline in hemoglobin A1c (HbA1c) [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Blood samples were collected to analyze HbA1c.

  • Change from baseline in 2 hour glucose post oral glucose tolerance test (OGTT) [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]
    Blood samples were collected to analyze the 2 hour glucose post OGTT.

  • Change from baseline in beta cell function (HOMA-B) and insulin resistance (HOMA-R) [ Time Frame: baseline, 12 weeks, 48 weeks ] [ Designated as safety issue: No ]

    Blood samples were collected to analyze beta cell function and insulin resistance. Beta cell function and insulin resistance were calculated by the Homeostasis Model Assessments (of beta cell function (HOMA-B) and of insulin resistance (HOMA-IR)) as follows:

    HOMA-B: The product of 20 and basal insulin (µU/mL) levels divided by the value of basal glucose (mmol/L) concentrations minus 3.5 [i.e., HOMA-B = 20*basal insulin/(basal glucose-3.5)]. HOMA-IR: The product of basal glucose (mmol/L) and insulin (µU/mL) levels divided by 22.5 [i.e., HOMA-IR = basal glucose*basal insulin/22.5].

Enrollment: 189
Study Start Date: December 2009
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
Experimental: ACZ885
150 mg
Drug: ACZ885
ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Other Name: Canakinumab


Ages Eligible for Study:   18 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with known atherosclerotic disease and documented diagnosis of T2DM for ≤ 14 years OR IGT
  • HbA1c between 6.0% and 10.0%
  • On stable statin therapy or statin intolerant
  • Patients who are eligible and able to participate in the study

Exclusion Criteria:

  • Contraindications to MRI
  • NYHA class IV Heart Failure
  • NYHA class I - III heart failure with acute exacerbation in 3 months prior to screening
  • Patients with type 1 diabetes
  • Acute infections
  • HsCRP > 30 mg/dL
  • Aortic aneurysm ≥5cm

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00995930

United States, New York
Novartis Investigative Site
New York, New York, United States, 10029
United States, Ohio
Novartis Investigative Site
Cincinnati, Ohio, United States, 45219
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H1T 1C8
Novartis Investigative Site
Mainz, Germany, 55116
Novartis Investigative Site
Neuss, Germany, 41460
Novartis Investigative Site
Ulm, Germany, 89081
Novartis Investigative Site
Jerusalem, Israel, 91120
United Kingdom
Novartis Investigative Site
Oxford, UK, United Kingdom, OX2 6HE
Novartis Investigative Site
London, United Kingdom, EC1M 6BQ
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT00995930     History of Changes
Other Study ID Numbers: CACZ885I2206, 2009-014618-80
Study First Received: October 15, 2009
Last Updated: January 28, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Germany: Paul-Ehrlich-Institut
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Ministry of Health

Keywords provided by Novartis:
Type 2 Diabetes Mellitus, T2DM,
Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Prediabetic State
Arterial Occlusive Diseases
Cardiovascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases processed this record on March 03, 2015